Addition of interleukin-21 for expansion of T-cells for adoptive immunotherapy of murine melanoma

International Journal of Molecular Sciences

Volumn 16, Issue 4, 2015, Pages 8744-8760

  Zoon, Christine Kathryn ^a   Wan, Wen ^a   Graham, Laura ^b   Bear, Harry D ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Adoptive immunotherapy; IL 15; IL 2; IL 21; IL 7; Melanoma

Indexed keywords

BRYOSTATIN 1; GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7; IONOMYCIN; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN DERIVATIVE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CELL EXPANSION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IN VITRO STUDY; MELANOMA; METASTASIS; MOUSE; NONHUMAN; QUANTITATIVE ASSAY; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; COCULTURE; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; METABOLISM; PATHOLOGY; PHYSIOLOGY; SECONDARY; T LYMPHOCYTE;

MURINAE; MUS;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKINS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES;

EID: 84928139237     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16048744     Document Type: Article

References (41)

1. Klebanoff, C.A.; Gattinoni, L.; Palmer, D.C.; Muranski, P.; Ji, Y.; Hinrichs, C.S.; Borman, Z.A.; Kerkar, S.P.; Scott, C.D.; Finkelstein, S.E., et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 2011, 17, 5343–5352.
2. Pouw, N.; Treffers-Westerlaken, E.; Kraan, J.; Wittink, F.; ten Hagen, T.; Verweij, J.; Debets, R. Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T Cells. Cancer Immunol. Immunother. 2010, 59, 921–931.
3. Huarte, E.; Fisher, J.; Turk, M.J.; Mellinger, D.; Foster, C.; Wolf, B.; Meehan, K.R.; Fadul, C.E.; Ernstoff, M.S. Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. Cancer Lett. 2009, 285, 80–88.
4. Bear, H.D.; Roberts, J.; Cornell, D.; Tombes, M.B.; Kyle, B. Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: A pilot clinical trial. Cancer Immunol. Immunother. 2001, 50, 269–274.
5. Liu, S.; Riley, J.; Rosenberg, S.; Parkhurst, M. Comparison of common γ-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy. J. Immunother. 2006, 29, 284–293.
6. Le, H.K.; Graham, L.; Miller, C.H.; Kmieciak, M.; Manjili, M.H.; Bear, H.D. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2. Cancer Immunol. Immunother. 2009, 58, 1565–1576.
7. Chatila, T.; Silverman, L.; Miller, R.; Geha, R. Mechanisms of T cell activation by the calcium ionophore ionomycin. J. Immunol. 1989, 143, 1283–1289.
8. Kazanietz, M.G.; Lewin, N.E.; Gao, F.; Pettit, G.R.; Blumberg, P.M. Binding of [26–3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes. Mol. Pharmacol. 1994, 46, 374–379.
9. Pettit, G.R.; Herald, S.L.; Doubek, D.L.; Arnold, E.; Clardy, J. Isolation and structure of bryostatin 1. J. Am. Chem. Soc. 1982, 104, 6846–6848.
10. Payne, K.K.; Zoon, C.K.; Wan, W.; Marlar, K.; Keim, R.C.; Kenari, M.N.; Kazim, A.L.; Bear, H.D.; Manjili, M.H. Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/Neu reactivity and overcome myeloid-derived suppressor cells. Breast Cancer Res. Treat. 2013, 142, 45–57.
11. Kmieciak, M.; Basu, D.; Payne, K.K.; Toor, A.; Yacoub, A.; Wang, X.Y.; Smith, L.; Bear, H.D.; Manjili, M.H. Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse. J. Immunol. 2011, 187, 708–717.
12. Kmieciak, M.; Toor, A.; Graham, L.; Bear, H.D.; Manjili, M.H. Ex vivo expansion of tumor-reactive t cells by means of bryostatin 1/ionomycin and the common γ chain cytokines formulation. J. Vis. Exp. 2011, 47, doi:10.3791/2381.
13. Miller, C.H.; Graham, L.; Bear, H.D. Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma. BMC Immunol. 2010, 11, doi:10.1186/1471-2172-11-54.
14. Cha, E.; Graham, L.; Manjili, M.H.; Bear, H.D. IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo. Breast Cancer Res. Treat. 2010, 122, 359–369.
15. Chin, C.S.; Miller, C.H.; Graham, L.; Parviz, M.; Zacur, S.; Patel, B.; Duong, A.; Bear, H.D. Bryostatin 1/Ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes. Int. Immunol. 2004, 16, 1283–1294.
16. Parviz, M.; Chin, C.S.; Graham, L.J.; Miller, C.; Lee, C.; George, K.; Bear, H.D. Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model. Cancer Immunol. Immunother. 2003, 52, 739–750.
17. Klebanoff, C.A.; Gattinoni, L.; Torabi-Parizi, P.; Kerstann, K.; Cardones, A.R.; Finkelstein, S.E.; Palmer, D.C.; Antony, P.A.; Hwang, S.T.; Rosenberg, S.A., et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. USA 2005, 102, 9571–9576.
18. Gattinoni, L.; Klebanoff, C.A.; Palmer, D.C.; Wrzesinski, C.; Kerstann, K.; Yu, Z.; Finkelstein, S.E.; Theoret, M.R.; Rosenberg, S.A.; Restifo, N.P. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T Cells. J. Clin. Investig. 2005, 115, 1616–1626.
19. Parrish-Novak, J.; Dillon, S.R.; Nelson, A.; Hammond, A.; Sprecher, C.; Gross, J.A.; Johnston, J.; Madden, K.; Xu, W.; West, J., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000, 408, 57–63.
20. Spolski, R.; Leonard, W.J. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol. 2008, 26, 57–79.
21. Leonard, W.J.; Spolski, R. Interleukin-21: A modulator of lymphoid proliferation, apoptosis and differentiation. Nat. Rev. Immunol. 2005, 5, 688–698.
22. Wolfl, M.; Merker, K.; Morbach, H.; van Gool, S.W.; Eyrich, M.; Greenberg, P.D.; Schlegel, P.G. Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy. Cancer Immunol. Immunother. 2011, 60, 173–186.
23. Singh, H.; Figliola, M.J.; Dawson, M.J.; Huls, H.; Olivares, S.; Switzer, K.; Mi, T.; Maiti, S.; Kebriaei, P.; Lee, D.A., et al. Reprogramming CD19-Specific T Cells with IL-21 Signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 2011, 71, 3516–3527.
24. Chapuis, A.G.; Ragnarsson, G.B.; Nguyen, H.N.; Chaney, C.N.; Pufnock, J.S.; Schmitt, T.M.; Duerkopp, N.; Roberts, I.M.; Pogosov, G.L.; Ho, W.Y., et al. Transferred WT1-Reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci. Transl. Med. 2013, 5, doi:10.1126/scitranslmed.3004916.
25. Hinrichs, C.S.; Spolski, R.; Paulos, C.M.; Gattinoni, L.; Kerstann, K.W.; Palmer, D.C.; Klebanoff, C.A.; Rosenberg, S.A.; Leonard, W.J.; Restifo, N.P. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 2008, 111, 5326–5333.
26. Brentjens, R.J.; Latouche, J.B.; Santos, E.; Marti, F.; Gong, M.C.; Lyddane, C.; King, P.D.; Larson, S.; Weiss, M.; Riviere, I., et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and Interleukin-15. Nat. Med. 2003, 9, 279–286.
27. Di Carlo, E.; Comes, A.; Orengo, A.M.; Rosso, O.; Meazza, R.; Musiani, P.; Colombo, M.P.; Ferrini, S. IL-21 Induces tumor rejection by specific CTL and IFN-γ-dependent CXC Chemokines in Syngeneic Mice. J. Immunol. 2004, 172, 1540–1547.
28. Klebanoff, C.A.; Finkelstein, S.E.; Surman, D.R.; Lichtman, M.K.; Gattinoni, L.; Theoret, M.R.; Grewal, N.; Spiess, P.J.; Antony, P.A.; Palmer, D.C., et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. USA 2004, 101, 1969–1974.
29. Sondergaard, H.; Frederiksen, K.S.; Thygesen, P.; Galsgaard, E.D.; Skak, K.; Kristjansen, P.E.; Odum, N.; Kragh, M. Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors. Cancer Immunol. Immunother. 2007, 56, 1417–1428.
30. Teague, R.M.; Sather, B.D.; Sacks, J.A.; Huang, M.Z.; Dossett, M.L.; Morimoto, J.; Tan, X.; Sutton, S.E.; Cooke, M.P.; Ohlen, C., et al. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat. Med. 2006, 12, 335–341.
31. Zeng, R.; Spolski, R.; Finkelstein, S.E.; Oh, S.; Kovanen, P.E.; Hinrichs, C.S.; Pise-Masison, C.A.; Radonovich, M.F.; Brady, J.N.; Restifo, N.P., et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 2005, 201, 139–148.
32. Kasaian, M.T.; Whitters, M.J.; Carter, L.L.; Lowe, L.D.; Jussif, J.M.; Deng, B.; Johnson, K.A.; Witek, J.S.; Senices, M.; Konz, R.F., et al. IL-21 limits NK Cell responses and promotes antigen-specific T cell activation: A mediator of the transition from innate to adaptive immunity. Immunity 2002, 16, 559–569.
33. Moroz, A.; Eppolito, C.; Li, Q.; Tao, J.; Clegg, C.H.; Shrikant, P.A. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: Comparative evaluation of IL-2, IL-15, and IL-21. J. Immunol. 2004, 173, 900–909.
34. Li, Y.; Bleakley, M.; Yee, C. IL-21 Influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J. Immunol. 2005, 175, 2261–2269.
35. Hinrichs, C.S.; Borman, Z.A.; Gattinoni, L.; Yu, Z.; Burns, W.R.; Huang, J.; Klebanoff, C.A.; Johnson, L.A.; Kerkar, S.P.; Yang, S., et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 2011, 117, 808–814.
36. Albrecht, J.; Frey, M.; Teschner, D.; Carbol, A.; Theobald, M.; Herr, W.; Distler, E. IL-21-treated naive CD45RA+CD8+ T cells represent a reliable source for producing leukemia-reactive cytotoxic T lymphocytes with high proliferative potential and early differentiation phenotype. Cancer Immunol. Immunother. 2011, 60, 235–248.
37. Gattinoni, L.; Klebanoff, C.A.; Restifo, N.P. Paths to stemness: Building the ultimate antitumour T cell. Nat. Rev. Cancer 2012, 12, 671–684.
38. Lipshy, K.A.; Kostuchenko, P.J.; Hamad, G.G.; Bland, C.E.; Barrett, S.K.; Bear, H.D. Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma. Ann. Surg. Oncol. 1997, 4, 334–341.
39. Wherry, E.J.; Teichgraber, V.; Becker, T.C.; Masopust, D.; Kaech, S.M.; Antia, R.; von Andrian, U.H.; Ahmed, R. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 2003, 4, 225–234.
40. Parish, I.A.; Kaech, S.M. Diversity in CD8+ T cell differentiation. Curr. Opin. Immunol. 2009, 21, 291–297.
41. Obar, J.J.; Lefrancois, L. Memory CD8+ T cell differentiation. Ann. N. Y. Acad. Sci. 2010, 1183, 251–266.